Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Acquired by Murchinson Ltd.

Murchinson Ltd. increased its position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 23.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 1,699,990 shares of the biotechnology company’s stock after acquiring an additional 320,495 shares during the period. Oramed Pharmaceuticals comprises about 0.7% of Murchinson Ltd.’s holdings, making the stock its 20th biggest position. Murchinson Ltd.’s holdings in Oramed Pharmaceuticals were worth $4,369,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. XTX Topco Ltd acquired a new position in Oramed Pharmaceuticals during the second quarter worth approximately $40,000. Renaissance Technologies LLC increased its position in Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Oramed Pharmaceuticals during the first quarter worth approximately $68,000. Institutional investors and hedge funds own 12.73% of the company’s stock.

Oramed Pharmaceuticals Stock Up 3.3 %

ORMP opened at $2.48 on Friday. Oramed Pharmaceuticals Inc. has a 52-week low of $1.67 and a 52-week high of $3.67. The company has a 50 day moving average of $2.41 and a two-hundred day moving average of $2.45. The company has a market cap of $101.11 million, a P/E ratio of 9.54 and a beta of 1.77.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.21. Research analysts anticipate that Oramed Pharmaceuticals Inc. will post 0.24 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th. StockNews.com lowered shares of Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday.

Oramed Pharmaceuticals Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.